You are here: Industry Insights > surufatinib

News List

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors prnasia
June 22, 2021
HUTCHMED (China) Limited announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration of China ("NMPA") for the treatment of advanced pancreatic neuroendocrine tumors ("pNETs").
Chi-Med, BeiGene Enter Clinical Collaboration contractpharma
May 27, 2020
Will evaluate combinations of surufatinib and fruquintinib with tislelizumab for multiple solid tumor cancer indications.
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors En-CPhI.CN
October 12, 2019
Innovent Biologics, Inc. and Hutchison China MediTech Limited announced the expansion of their global collaboration agreement to evaluate the safety and efficacy of Innovent's Tyvyt® (sintilimab injection) ...
Chi-Med’s Surufatinib Study Meets Primary Endpoint Early contractpharma
July 04, 2019
Stops Phase III study of surufatinib in advanced neuroendocrine tumors, meeting the primary endpoint of progression free survival.